Splenectomy in Hodgkinʼs disease
- 1 August 1982
- journal article
- research article
- Published by Wolters Kluwer Health in American Journal of Clinical Oncology
- Vol. 5 (4) , 393-398
- https://doi.org/10.1097/00000421-198208000-00008
Abstract
A total of 124 patients with advanced Hodgkin''s disease were treated uniformly with combination chemotherapy and radiotherapy. Splenectomy was not performed in 32 patients due to obvious stage IV disease, a medical contraindication or patient refusal. Comparison of the splenectomy and nonsplenectomy patients revealed no differences in nadir white blood cell counts, platelet counts or the total dosages of drugs that were administered. Survival and disease free survival curves with a 5-yr median follow up also failed to show any difference in the 2 groups. Splenectomy does not offer a therapeutic advantage in those patients whose treatment would not be altered by splenic histology.This publication has 2 references indexed in Scilit:
- Curative potential of combined modality therapy for advanced Hodgkin's diseaseCancer, 1980
- Splenectomy, chemotherapy, and survival in Hodgkin diseaseArchives of internal medicine (1960), 1977